Caricamento...
Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer
ErbB2, a member of the ErbB family of receptor tyrosine kinases, is an essential player in the cell’s growth and proliferation signaling pathways. Amplification or overexpression of ErbB2 is observed in ∼30% of breast cancer patients, and often drives cellular transformation and cancer development....
Salvato in:
| Pubblicato in: | Cell Death Dis |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Nature Publishing Group UK
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5833446/ https://ncbi.nlm.nih.gov/pubmed/29352243 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-017-0067-7 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|